- World Pharma News Home » Clinical Trials » ADAGIO trial results show Azilect® slows progression of Parkinson's disease
(a free service delivered by FeedBurner)
Lundbeck's partner Teva Pharmaceutical Industries Ltd. has announced that results of the phase III ADAGIO trial were presented during the 12th Congress of European Federation of Neurological Societies (EFNS) in Madrid, Spain. The ADAGIO study showed that Parkinson's disease patients who took Azilect® (rasagiline) 1mg tablets once-daily upon entry into the trial, demonstrated a significant improvement compared to those who initiated therapy with the drug nine months later. The 1mg dose met all three primary endpoints, as well as the secondary endpoint, with statistical significance.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments